journal
Journals Innovations in Clinical Neuros...

Innovations in Clinical Neuroscience

https://read.qxmd.com/read/38495611/health-anxiety-fear-of-covid-19-nosophobia-and-health-protective-behaviors-among-healthcare-professionals
#1
JOURNAL ARTICLE
Uzma Ilyas, Farwa Aslam, Muqadas Fatima, Zarmin Tariq, Usman Hotiana
OBJECTIVE: This study examined fear of COVID-19, nosophobia, health anxiety, and health-protective behaviors among healthcare professionals during the COVID-19 pandemic. METHODS: A cross-sectional, correlational research design was used in this study. The data of healthcare professionals (N=300) from three disciplines of medicine (Bachelor of Medicine and Bachelor of Surgery [MBBS], Bachelor of Dental Surgery [BDS], Doctor of Physiotherapy [DPT]) were collected using a purposive sampling technique...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495610/risk-management-blurring-the-lines-boundary-violation
#2
JOURNAL ARTICLE
Akemini Kem Isang
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495609/current-and-emerging-technologies-to-address-the-placebo-response-challenge-in-cns-clinical-trials-promise-pitfalls-and-pathways-forward
#3
REVIEW
William P Horan, Gary Sachs, Dawn I Velligan, Michael Davis, Richard S E Keefe, Ni A Khin, Florence Butlen-Ducuing, Philip D Harvey
Excessive placebo response rates have long been a major challenge for central nervous system (CNS) drug discovery. As CNS trials progressively shift toward digitalization, decentralization, and novel remote assessment approaches, questions are emerging about whether innovative technologies can help mitigate the placebo response. This article begins with a conceptual framework for understanding placebo response. We then critically evaluate the potential of a range of innovative technologies and associated research designs that might help mitigate the placebo response and enhance detection of treatment signals...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495608/functioning-and-cognition-in-patients-with-schizophrenia-after-initiating-treatment-with-aripiprazole-lauroxil-secondary-outcomes-and-post-hoc-analysis
#4
JOURNAL ARTICLE
Mark G A Opler, Amy Claxton, James McGrory, Sabina Gasper, Meihua Wang, Sergey Yagoda
BACKGROUND: Clinical practice guidelines support efforts to improve functioning in patients with schizophrenia. Discrepancies in the perception of cognitive status between clinicians, patients with schizophrenia, and their caregivers have been associated with impaired functional abilities in patients; medication side effects might worsen both cognition and daily functioning. We assessed daily/social functioning and cognition in stable patients with schizophrenia who switched to the long-acting injectable (LAI) antipsychotic aripiprazole lauroxil (AL)...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495607/the-catastrophic-perception-of-pain-in-burning-mouth-syndrome-may-be-associated-with-sympathetic-tone-as-indicated-by-the-qtc-interval
#5
JOURNAL ARTICLE
Takahiko Nagamine, Takeshi Watanabe
No abstract text is available yet for this article.
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495606/impact-of-covid-19-pandemic-on-patients-with-serious-mental-illness-smi-and-nonpsychiatric-control-subjects-in-clinical-trials
#6
JOURNAL ARTICLE
Maria Fe Garcia-Rada, Robert E Litman
OBJECTIVE: This study aimed to examine the impact of the COVID-19 pandemic on patients with serious mental illness (SMI), specifically relating to psychiatric morbidity, pandemic-induced stress, and ability to cope with pandemic-related precautionary measures, restrictions, and disruptions to daily life. DESIGN: A cross-sectional survey study of 277 clinical trial patients was conducted. This sample included nonpsychiatric controls (n=139) and patients with a diagnosis of bipolar disorder, major depressive disorder (MDD), or schizophrenia (n=138) located at five clinical trial sites across the United States...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495605/psychotherapy-s-role-in-evaluating-the-invisible-wounds-of-moral-injury
#7
REVIEW
Ben Onnink, Matthew C Correll, Andrew Correll, Terry Correll
Moral injury is a relatively new concept with varying definitions that attempts to define a profound and lasting insult to one's conscience caused by perpetration of or directly witnessing harm to another person in a high-pressure situation. This entity is separate from posttraumatic stress disorder (PTSD), but it can coexist with PTSD. This article provides psychotherapeutic examples of the diagnosis of moral injury from a psychodynamic perspective, focusing on morally challenging situations related to warfare and the healthcare system...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495604/genesis-of-mental-disorders-could-it-be-cavum-septum-pellucidum-csp-et-vergae-a-case-report-of-csp-in-schizophrenia-with-catatonia
#8
Allison Zuckerberg, Nitin Pothen, Adriana Fitzsimmons
In our case report, a 29-year-old male patient with a known history of schizophrenia presented with altered mental status and catatonia and was found to have an enlarged (21mm) cavum septum pellucidum (CSP) on magnetic resonance imaging (MRI). He was subsequently treated with escitalopram, olanzapine, methylphenidate, lorazepam, and eight electroconvulsive therapy (ECT) treatments during his hospital course, after which his catatonia improved. We compared this to other cases in which a large CSP was identified and discussed the possibility of increased susceptibility to psychosis, specifically catatonia, which might be associated with this developmental anomaly...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495603/ensuring-stakeholder-feedback-in-the-design-and-conduct-of-clinical-trials-for-rare-diseases-isctm-position-paper-of-the-orphan-disease-working-group
#9
REVIEW
Gahan J Pandina, Joan Busner, Lucas Kempf, Joan Fallon, Larry D Alphs, Maria T Acosta, Anna-Karin Berger, Simon Day, Judith Dunn, Victoria Villalta-Gil, Margaret C Grabb, Joseph P Horrigan, William Jacobson, Judith C Kando, Thomas A Macek, Manpreet K Singh, Arielle D Stanford, Silvia Zaragoza Domingo
The 1983 Orphan Drug Act in the United States (US) changed the landscape for development of therapeutics for rare or orphan diseases, which collectively affect approximately 300 million people worldwide, half of whom are children. The act has undoubtedly accelerated drug development for orphan diseases, with over 6,400 orphan drug applications submitted to the US Food and Drug Administration (FDA) from 1983 to 2023, including 350 drugs approved for over 420 indications. Drug development in this population is a global and collaborative endeavor...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495602/artificial-intelligence-and-neurorehabilitation-fact-vs-fiction
#10
EDITORIAL
Nicola Fiorente, Sepehr Mojdehdehbaher, Rocco Salvatore Calabrò
Artificial intelligence (AI) encompasses computer systems that mimic human cognitive functions, performing tasks such as learning, reasoning, problem solving, and decision-making. Neurorehabilitation is a specialized healthcare field aiding individuals with neurological injuries, employing various therapies to restore motor skills and cognitive function, enhancing their quality of life. The integration of AI in neurorehabilitation holds great promise, but it is crucial to approach this technology with a clear understanding of its capabilities and limitations...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495601/chatgpt-and-transcranial-direct-current-stimulation-for-chronic-pain
#11
EDITORIAL
Edson Silva-Filho, Rodrigo Pegado
OBJECTIVE: We aimed to open a discussion about the integration of artificial intelligence (AI) in science and clinical practice, specifically with regard to the use of transcranial direct current stimulation (tDCS) as a technique for managing chronic pain. MAIN POINTS OF DISCUSSION: To analyze the responses generated by ChatGPT and the best literature about tDCS, we formulated three questions. The answers from ChatGPT, compared to the guidelines and Cochrane review, showed that AI can be a potential strategy to help clinicians and researchers...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193107/risk-management-pop-quiz-answers
#12
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193106/treating-psychiatric-symptoms-in-persistent-postural-perceptual-dizziness
#13
REVIEW
Jonathan R Scarff, Steven Lippmann
Persistent postural perceptual dizziness (PPPD) is a functional neurological disorder characterized by troublesome feelings of dizziness and might be precipitated by vestibular events, postural changes, psychopathologies, and/or a person's perceptual experiences. The diagnosis is confirmed by assessing a patient's history. A variety of psychiatric symptoms are associated with PPPD; anxiety and depression are the most common. Psychotherapy and pharmacotherapy can be clinically helpful in reducing psychiatric symptoms and dizziness...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193105/risk-management-pop-quiz
#14
JOURNAL ARTICLE
Donna Vanderpool
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193104/impact-of-covid-19-on-the-mental-health-of-psychiatric-inpatients
#15
JOURNAL ARTICLE
Samara White, Tammie Lee Demler, Eileen Trigoboff, Lucy Keers, Chloe Matecki
PURPOSE: The perceptions and responses to acute states of emergency may vary for people experiencing serious mental illness (SMI). Therefore, studying the mental health toll of the COVID-19 pandemic on psychiatric inpatients can inform psychiatric care in the event of future global crises. The objective of this study was to determine if there was a difference in the incidence of mental health manifestations in an adult inpatient state psychiatric facility during the COVID-19 pandemic, compared to the immediately preceding year...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193103/the-challenge-of-somatic-variants-in-focal-cortical-dysplasia
#16
Joana Jesus-Ribeiro, Luís Miguel Pires, Ilda Patrícia Ribeiro, Olinda Rebelo, Ricardo Pereira, Francisco Sales, Isabel Santana, António Freire, Joana Barbosa Melo
OBJECTIVE: The advent of next-generation sequencing (NGS) enabled the detection of low-level brain somatic variants in postsurgical tissue of focal cortical dysplasia (FCD). The genetic background of FCD Type I remains elusive, while the mammalian target of rapamycin (mTOR) pathway seems to have a relevant role in the pathogenesis of FCD Type II. Our goal was to uncover information on the molecular basis of FCD, performing whole genome sequencing (WGS) in postsurgical tissue to detect candidate brain-specific somatic variants, and evaluate their clinical significance...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193102/impact-of-the-medication-shortages-on-psychiatric-patients-exploring-the-consequences-of-lorazepam-injection-scarcity
#17
JOURNAL ARTICLE
Yael Marks, Tammie Lee Demler, Chloe Matecki
OBJECTIVE: This study reviewed the cases of 13 patients in a psychiatric hospital during the 2022 lorazepam injection shortage in the United States (US). The objective was to determine if there were any patterns to the management of the medication shortage of an essential psychiatric medication at a psychiatric hospital. METHODS: A retrospective review of eligible patients who had an order for lorazepam injection prescribed as needed (PRN) between July and October 2022 were divided into, and compared between, two groups: those who had orders permitting continued PRN administration of the medication and those who were discontinued...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193101/addressing-structural-racism-in-child-and-adolescent-psychiatry-in-psychotherapy
#18
REVIEW
Sydnee Akubuiro, Wendy Clay, Suzie Nelson, Allison E Cowan
The increase in mental health issues among children and adolescents has been declared a health crisis in the United States, and recent increases in key measures (e.g., self-harm and suicidal behaviors) have been found to disproportionately impact youth from minority backgrounds. Access to mental health treatment for youth is limited, but for minority youth, access to culturally sensitive care is even more limited. This article discusses the ways in which misdiagnosis and underdiagnosis of mental health conditions can occur in minority youth and provides key points for clinicians to consider while working with minority youth to improve mental health outcomes...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193100/outpatient-pharmacogenomic-screenings-to-prevent-addiction-overdose-and-suicide
#19
JOURNAL ARTICLE
Atmaram Yarlagadda, Kevin Swift, Nabarun Chakraborty, Rasha Hammamieh, Amina Abubakar, Marianna Wilbur, Anita H Clayton
Point-of-care genetic testing for single nucleotide polymorphisms (SNPs) to improve psychiatric treatment in outpatient settings remains a challenge. The presence or absence of certain genomic alleles determines the activity of the encoded enzymes, which ultimately defines the individual's drug metabolism rate. Classification of poor metabolizers (PMs) and rapid/ultrarapid metabolizers (RMs/UMs) would facilitate personalization and precision of treatment. However, current pharmacogenomic (PGx) testing of multiple genes is comprehensive and requires quantitative analyses for interpretations...
2023: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38193099/left-ventricular-noncompaction-cardiomyopathy-diagnosis-in-a-patient-presenting-with-epileptic-seizure-a-double-edged-sword
#20
Eirini Beneki, Kyriakos Dimitriadis, Konstantinos Tsatiris, Konstantina Aggeli, Konstantinos Tsioufis
Transient loss of consciousness (TLOC) is a common presentation to emergency departments and may be due to syncope or epileptic seizures. The distinction between both entities can be challenging. This case illustrates the need for a multidisciplinary team approach in TLOC to avoid misdiagnosis leading to improper treatment.
2023: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.